RNA-seq profiling of white and brown adipocyte differentiation treated with epigallocatechin gallate

Pengpeng Zhang, Wei Wu, Chunyu Du, Xiang Ji, Yaling Wang, Qiu Han, Hiaxia Xu, Cencen Li, Yongjie XuScientific 2022 · DOI

Abstract

Due to serious adverse effects, many of the approved anti-obesity medicines have been withdrawn, and the selection of safer natural ingredients is of great interest. Epigallocatechin gallate (EGCG) is one of the major green tea catechins, and has been demonstrated to possess an anti-obesity function by regulating both white and brown adipose tissue activity. However, there are currently no publicly available studies describing the effects of EGCG on the two distinct adipose tissue transcriptomes. The stromal vascular fraction (SVF) cell derived from adipose tissue is a classic cell model for studying adipogenesis and fat accumulation. In the current study, primary WAT and BAT SVF cells were isolated and induced to adipogenic differentiation in the presence or absence of EGCG. RNA-seq was used to determine genes regulated by EGCG and identify the key differences between the two functionally distinct adipose tissues. Taken together, we provide detailed stage- and tissue-specific gene expression profiles affected by EGCG. These data will be valuable for obesity-related clinical/basic research.

Introduction

Obesity is driven by the expansion of adipose tissue through two processes: hyperplasia (forming new fat cells) and hypertrophy (enlarging existing ones). Humans and mice possess two main types of fat: White Adipose Tissue (WAT), which stores energy as large lipid droplets, and Brown Adipose Tissue (BAT), which burns energy to generate heat (thermogenesis). While epigallocatechin gallate (EGCG) is widely recognized for its anti-obesity properties, the molecular mechanisms by which it influences these two functionally distinct tissues remain poorly understood. This study addresses the lack of comparative transcriptomic data showing how EGCG affects the gene expression program during the transition from precursor cells to mature adipocytes in both WAT and BAT.

Methods

The researchers used a classic cell model: Stromal Vascular Fraction (SVF) cells isolated from the inguinal WAT and interscapular BAT of 6-week-old C57BL/6 J mice. Cells were induced to differentiate and treated with either 5 μM of EGCG or a DMSO control from Day 4 to Day 8.

Experimental and bioinformatics workflow for RNA-seq analysis of WAT and BAT SVF cells.

Total RNA was sequenced using the Illumina HiSeq 4000 platform. The bioinformatics pipeline included quality control (FastQC, fastp), alignment to the mm9 reference genome (HISAT2), and differential expression analysis using DESeq2. Batch effects from sequencing the third biological replicate separately were corrected using the ComBat_Seq function.

Results

The study generated a total of 24 RNA-seq samples (accession SRP318155) with high data quality, showing an average mapping rate of 90.70%.

EGCG as a Differentiation Brake

Morphological analysis via Oil Red O staining demonstrated that EGCG acts as a potent inhibitor of adipogenesis. Treated cells showed significantly fewer and smaller lipid droplets compared to controls by Day 8. This visual evidence was corroborated by the significant downregulation of master adipogenic marker genes, including Pparγ, Fabp4, Adiponectin, and Plin1.

Morphological changes (Oil Red O staining) and relative mRNA expression of adipogenic and thermogenic markers in WAT and BAT.

Tissue-Specific Signatures and Thermogenic Markers

Despite the inhibitory effect on both tissues, PCA analysis showed that WAT and BAT maintain highly distinct transcriptomic identities throughout the treatment. Real-time PCR validated that BAT cells expressed approximately 30 times more Ucp1 (the primary protein responsible for heat production) than WAT cells, confirming the functional integrity of the brown adipocyte model. The study also highlighted several novel differentially expressed genes (DEGs) such as Cep170b, Pdpn, and Slc39a6, providing new leads for mechanistic research.

Discussion

This research provides a comprehensive stage- and tissue-specific gene expression profile affected by EGCG. While the dataset is robust and reproducible, the authors note that as an in vitro study, these results reflect the direct effects of EGCG on adipocytes. Future work is required to determine if these gene expression changes occur in a complex in vivo physiological environment. Additionally, the specific roles of novel DEGs like Cep170b in EGCG-mediated weight loss remain to be functionally characterized.

Summary updated

Abstract

Due to serious adverse effects, many of the approved anti-obesity medicines have been withdrawn, and the selection of safer natural ingredients is of great interest. Epigallocatechin gallate (EGCG) is one of the major green tea catechins, and has been demonstrated to possess an anti-obesity function by regulating both white and brown adipose tissue activity. However, there are currently no publicly available studies describing the effects of EGCG on the two distinct adipose tissue transcriptomes. The stromal vascular fraction (SVF) cell derived from adipose tissue is a classic cell model for studying adipogenesis and fat accumulation. In the current study, primary WAT and BAT SVF cells were isolated and induced to adipogenic differentiation in the presence or absence of EGCG. RNA-seq was used to determine genes regulated by EGCG and identify the key differences between the two functionally distinct adipose tissues. Taken together, we provide detailed stage- and tissue-specific gene expression profiles affected by EGCG. These data will be valuable for obesity-related clinical/basic research.
BibTeX
@inproceedings{zhang2022rna,
  author = {Pengpeng Zhang and Wei Wu and Chunyu Du and Xiang Ji and Yaling Wang and Qiu Han and Hiaxia Xu and Cencen Li and Yongjie Xu},
  title = {{RNA-seq profiling of white and brown adipocyte differentiation treated with epigallocatechin gallate}},
  booktitle = {Scientific},
  year = {2022},
  doi = {10.1038/s41597-022-01149-0},
}
Figure